CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $959,115 | +107.4% | 32,250 | +25.7% | 0.01% | +100.0% |
| Q2 2023 | $462,483 | +13.4% | 25,665 | +1.0% | 0.00% | 0.0% |
| Q1 2023 | $407,908 | -10.5% | 25,399 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $455,542 | -7.2% | 24,893 | -0.4% | 0.00% | -25.0% |
| Q3 2022 | $491,000 | +7.0% | 24,984 | +1.4% | 0.00% | +33.3% |
| Q2 2022 | $459,000 | -8.6% | 24,630 | +7.6% | 0.00% | 0.0% |
| Q1 2022 | $502,000 | -27.9% | 22,881 | -6.6% | 0.00% | 0.0% |
| Q4 2021 | $696,000 | +61.5% | 24,492 | +19.6% | 0.00% | +50.0% |
| Q3 2021 | $431,000 | +11.9% | 20,479 | +0.2% | 0.00% | +100.0% |
| Q2 2021 | $385,000 | +59.8% | 20,439 | +29.6% | 0.00% | 0.0% |
| Q1 2021 | $241,000 | +8.6% | 15,771 | +0.3% | 0.00% | 0.0% |
| Q4 2020 | $222,000 | -12.6% | 15,730 | -2.8% | 0.00% | 0.0% |
| Q3 2020 | $254,000 | -12.4% | 16,181 | -2.2% | 0.00% | 0.0% |
| Q2 2020 | $290,000 | +202.1% | 16,549 | +153.2% | 0.00% | 0.0% |
| Q1 2020 | $96,000 | -44.5% | 6,537 | -5.5% | 0.00% | 0.0% |
| Q4 2019 | $173,000 | +64.8% | 6,914 | -0.8% | 0.00% | – |
| Q3 2019 | $105,000 | -40.3% | 6,972 | -0.7% | 0.00% | -100.0% |
| Q2 2019 | $176,000 | +40.8% | 7,022 | +28.2% | 0.00% | – |
| Q1 2019 | $125,000 | -9.4% | 5,478 | +19.5% | 0.00% | -100.0% |
| Q4 2018 | $138,000 | +4.5% | 4,585 | -0.8% | 0.00% | – |
| Q3 2018 | $132,000 | – | 4,620 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |